Status:
UNKNOWN
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hyperaldosteronism
Hypertension
Eligibility:
All Genders
20-60 years
Phase:
PHASE4
Brief Summary
we propose that bromocriptine may be an alternative treatment of primary aldosteronism, both APA and BAH.
Detailed Description
Primary aldosteronism (PA), a common curable disease of hypertension, is characterized by inappropriate production of aldosterone, which is at least partially autonomous of the renin-angiotensin syste...
Eligibility Criteria
Inclusion
- 20-60y/o hyperaldosteronsim patients
Exclusion
- Malignancy
- Bed-ridden
- Psychological disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00451672
Start Date
January 1 2007
End Date
December 1 2007
Last Update
March 23 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan Univserty Hospital
Taipei, Taiwan